

# **European Credit Strategy** Geoffrey Horton, CFA +44 (0) 20 3134 2680 geoffrey.horton@barclays.com

Barclays, UK

# **US Credit Strategy** Bradley Rogoff, CFA +1 212 412 7921 bradley.rogoff@barclays.com

BCI, US

Scott Schachter +1 212 526 9716 scott.schachter@barclays.com BCI, US

# Dissecting and Forecasting the CLO Equity Arb

The terms "equity arb," or just "the arb," are commonly used by CLO and loan investors when referring to the arbitrage opportunity created by buying loans and securitizing them using a CLO, receiving more in asset interest income than is paid out in CLO debt costs.

While the definition is clear, investors, managers, arrangers, and commentators rarely agree on what the CLO equity arb currently is, with the most common response being that "the arb is challenged." Thus, we dig into how the arb is measured, how it has actually moved, why seemingly simple calculations often lead to so many different opinions on the current arb level, and, finally, the best ways to measure the current estimated arb.

## The CLO Equity Arb Equation: Quantitative Factors

Because calculations for the arb can differ, we focus on the equity yield when discussing the direction and level of the arb, as this is the actual annual cash flow received by equity investors, compared with the more simple formula of asset interest minus CLO debt costs.

**Equity yield** = (Asset interest – CLO debt costs – management fees) / equity notional

Asset interest (+) – Calculating the equity yield of a CLO begins with the income generated from the underlying assets, primarily through interest payments. Interest income is driven by the coupons on the credits selected by the manger (eq, riskier credits should pay higher interest income); thus, the level of income is constantly changing as proceeds from repayments or sales are reinvested into credits with different coupons and the par value of the portfolio declines over time due to some par losses.

For our calculation of starting asset interest, we use each CLO's estimated target par value multiplied by the first reported weighted average spread (WAS) or coupon (WAC) following the effective date (when the collateral tests and limitations become effective). Anecdotally, CLO warehouses can remain outstanding for a few months up to a year, and deals take 3-6 months to become effective after closing (Figure ), so determining the actual asset spread level at pricing is difficult. Thus, our data for new starting equity yields are lagged by roughly a quarter until deals become effective.






Source: Barclays Research

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242. Barclays trades the securities covered in this report for its own account and on a discretionary basis on behalf of certain clients. Such trading interests may be contrary to the recommendations offered in this report. PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES STARTING AFTER PAGE 7

FIGURE 2


# US BSL CLO Initial Weighted Average Spread (WAS)



Source: Kanerai, Intex, Barclays Research

FIGURE 3

# EU CLO Initial Weighted Average Gross Coupon (WAC)




Source: Kanerai, Intex, Barclays Research

Since loans are immediately callable, a pickup in refinancings can also push interest income lower, decreasing the yield. For example, following the loan refi wave in 2016-17, initial CLO portfolio asset spreads in the US (Figure 2) and coupons in Europe (Figure 3) declined. To boost this part of the equation, CLO managers have increased exposure to riskier assets, including more B3-rated credits and lower-liquidity names, as discussed in *A CLOser Look inside the Matrix* (March 15, 2019).

• CLO debt costs (-) – New issue CLO debt costs (which are set at pricing) can be affected by the level of CLO supply, changes in demand from large buyer bases, differences in structure (eg, shorter reinvestment deals price tighter), and the value of CLOs relative to other segments of credit and securitized products. New issue CLO debt costs also tend to follow asset spreads, although CLOs lag because of differing holders and liquidity. Since 2011, there has been a higher correlation between weekly changes in new issue US CLO debt costs and two-week lagged BB/B loan spreads, compared with vice versa (ie, CLO debt costs are more likely to move in the direction of loan spreads, two weeks after the move in loans). However, CLOs typically have a two-year non-call period, ensuring that CLO debt costs remain constant for at least two years after pricing.

FIGURE 4


## US BSL CLO Initial Weighted Average Cost of Liabilities



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 5


## European CLO Initial Weighted Average Cost of Liabilities



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 6


## US BSL CLO Initial Management Fees



Source: Does not include fee rebates. Source: Intex, Barclays Research

#### FIGURE 7

#### European CLO Initial Management Fees




Source: Does not include fee rebates. Source: Intex, Barclays Research

• Management fees (-) – Finally, there are three management fees in a CLO: senior, subordinate, and incentive. The first two streams are recurring, while the incentive fee typically kicks in only when equity returns exceed 12%. The historical combined level of senior and sub fees has been 50bp, but the trend has been lower in the US (Figure 6) and Europe (Figure 7) recently, although fee rebates or side letters are not captured. We estimate that a 10bp fee cut equates to an approximately 1.0-1.5pt increase in equity return.

Putting together the pieces, we find that initial equity yields in the US (Figure 8) and Europe (Figure 9) have declined steadily since 2014. In the US, the median equity yield declined to 14.2% in 1Q19, a post-crisis quarterly low, or about 270bp lower than two years earlier in 1Q17. Similarly in Europe, the median equity yield declined to 14.9% in 1Q19, also a post-crisis quarterly low, and about 92bp lower than two years earlier in 1Q17. While the overall averages have trended lower, the dispersion around the average shows that some managers can still find ways to generate higher equity yields, while other yields are much lower than expected, possibly implying that other non-qualitative factors are at work or that these deal's equity is being retained or placed into risk-retention style funds, as noted in *On the Road- Notes from IMN NY 2019*.

FIGURE 8


## US BSL CLO Initial Equity Yields Have Slowly Declined...



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 9


## ... As Have European CLO Initial Equity Yields



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 10

Dispersion in Initial Equity Yields Has Also Decreased Slightly



Source: Kanerai, Intex, S&P LCD, Barclays Research

In line with the general decline in equity yields, dispersion by quarter has also decreased slightly. Since 2014, the difference between the 20th and 80th percentiles of initial equity yields has averaged 5.4% for US BSL CLOs and 2.4% for EU CLOs (Figure 10). This dispersion is likely driven by differences in CLO warehouse timing, manager trading skill, management fees, and debt execution. For example, a deal from a higher-tier manager could price with a lower cost of debt than a deal from a newer or lower-tier manager in the same period, improving the equity yield even if asset income levels are similar.

While initial equity yields have declined, the rate of decline has been slower recently. However, we find that the decline *could* have been much steeper had equity leverage not increased and fees not been lowered. Figure 11 shows that structural leverage (debt / equity balance) has been flat for US CLOs since 2014, but has risen steadily for EU CLOs.


The increase in leverage and decline in management fees have allowed initial equity yields to post less of a decline. If structural leverage were similar to 2014 levels and combined management fees were still 50bp, average initial equity yields for CLOs would be roughly 100-200bp lower than they are today (Figure 12).

FIGURE 11
Structural Leverage in Europe Has Increased Steadily since 2017



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 12
Without Leverage Increase and Fee Cuts, Yields Would Be
Lower



Source: Kanerai, Intex, S&P LCD, Barclays Research

#### The CLO Equity Arb Equation: Qualitative Factors

While the equity arb is typically considered the average excess spread currently available to equity investors, determining the optimal time to price a deal from an equity perspective is more complicated. The additional qualitative factors considered by equity investors can have a large effect on final equity returns.

Final equity return = Equity yield + document optionality – arranger fees – credit losses

Document optionality – This is harder to quantify, but looser indenture language allows
more manager flexibility when trading the portfolio or amending deal documentation.
Recently, this has included, but is not limited to, higher allowances for discount and
default swaps (CLO Managers' Distressed Debt Dilemma, August 2, 2019), lower purchase
price limits, higher risk asset buckets, more flexibility to trade post-reinvestment, and more
opportunities to flush par.

Valuing these embedded benefits is an imperfect science and can likely only be quuntified when the deal is terminated, as two managers with similar document stipulations can still react and trade in very different manners.

- Arranger fees A lower equity purchase price essentially equates to lower fees for arrangers. Under standard modelling assumptions, we estimate that a 2.5pt drop in equity purchase price equates to an additional 0.5-1.0pt in final equity returns. Because purchase prices can differ by investor type and are closely negotiated among the investor, arranger and manager, estimating purchase prices can be difficult.
- Credit losses Losses in the underlying portfolio are the last "cost" component. Credit losses depend on a number of factors, including manager capabilities, expected default cycles, underlying asset recoveries, and more. Typical pricing assumptions include 2% constant default rates and 65-70% recovery rates. A scenario where defaults are lower than the typical assumptions obviously creates a higher-than-expected return.

Thus, an initial low equity arb does not necessarily correlate to lower final returns, as equity yields are constantly evolving and hard-to-measure qualitative factors can provide additional benefits, but also additional downside, in specific future scenarios, as evidenced by pre-crisis deals where vintages with the lowest equity arb produced the highest IRRs.


However, as we argued in *CLO Equity: The Long and Short of It* (April 12, 2019), we think that longer-term equity investors should focus on what they can measure today – deals with higher starting yields to front-load cash flows and reduce market value risk from the final PO (principal only) payment.

# Measuring the Current CLO Equity Arb

While looking at *historical* equity yields using actual debt costs and effective asset coupons is important, the timelier, but also more difficult, assessment is the health of *current* equity yields, which leads to insight into the ultimate demand from new issue CLOs.


As noted above, our data are lagged by approximately a quarter, as we have to wait until CLOs become effective to have an idea of where asset income levels were when deals were initially priced. CLO debt costs, management fees, and leverage are typically slower moving, so determining the current asset income level arguably becomes the most influential (and difficult) variable in calculating the current equity yield. However, estimating when a CLO manager is purchasing assets, at what level, and whether it is being done in the primary or secondary market is a guessing game. As such, we took a simplistic approach to determining the best guide for current WAS, testing multiple S&P LCD loan indices, on both a lagged a non-lagged basis, to find the best approximate match.

FIGURE 13
US CLO WAS and LL Index Strongly Related since 2013



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 14
Few Periods When CLO WAS Higher Than LL Index Spread




Source: Kanerai, Intex, S&P LCD, Barclays Research

Using multiple loan indices available from S&P LCD, we found that the weighted average unlagged nominal spread of the S&P/LSTA Leveraged Loan Index had the highest R-squared with and lowest predicted differences (eg, residuals) from the initial median CLO WAS for US BSL CLOs (Figure 13). While there are periods when CLO WAS tends to be higher than the index (Figure 14), the overall trend and closeness in actual value tend to track quite well. Even when using the historical nominal spreads of the "BB-B" (BB/B 32%/68% current mix), "B-and Above," "Cov-lite," or "Loan 100" indices, or an average mix of new issue spreads, we found that using the larger loan index with no lag tracked the best.

However, for European CLOs, we found that a no-lagged mix of the weighted average nominal spreads of the BB and single-B indices tracked best, with the most optimal weighting being 65% of the single-B index and 35% of the BB index (Figure 15).

The R-squared and residuals of this sample were weaker than the US results, likely because of the illiquidity and smaller size of the EU loan market, as well as the fact that EU CLOs can purchase bonds. As such, the movement of the nominal mixed index spread versus EU CLO WAS (Figure 16) has a wider difference for brief a period, although the trend is still similar.

FIGURE 15 EU CLO WAS and Mixed Index Strongly Related since 2014



Source: Kanerai, Intex, S&P LCD, Barclays Research

FIGURE 16
Moves in Mixed Loan Index Also Close to EU CLO WAS



Source: Kanerai, Intex, S&P LCD, Barclays Research

Even though CLOs can have long purchase periods, as detailed in Figure 1, the R-squared of historical effective WAS to non-lagged nominal index spreads was always higher than when introducing a one- to three-month lag. In some sense, this suggests that CLOs are primarily priced as "print and sprint" transactions, skipping the longer warehousing period and instead quickly ramping up the portfolio using mostly secondary market transactions.


While some deals are done in this fashion, most CLOs are not. Thus, the reason non-lagged index spreads likely line up best with initial effective WAS is that both are weighted average nominal spreads (spreads over Libor or Euribor), not discounted secondary spreads. Because CLOs remain the largest holders of loans, at approximately 60% in the US and 45% in Europe (EU CLOs also buy high yield bonds), it makes sense that CLOs have asset coupons that closely represent the current loan market average, since pricing levels move much more slowly than secondary prices.

The largest difference between the asset profile of new issue CLOs and the loan market at time of pricing is likely to be in the asset spreads, or discounted margins (DMs), rather than average asset coupons. CLOs can be opportunistic when they purchase assets, especially if a warehouse is open during a period of high loan market volatility (eg, 4Q18), and end up with a very different average loan DM or weighted average price than the loan market would suggest at pricing. Thus, average asset coupons may match closely while other parts of the CLO structure could actually be benefiting (eg, from higher OC cushions).

With this understanding, and using the results from the index study above as a proxy for WAS, we estimate the current level of CLO equity yields in the US and Europe. Again, this is to provide a rough current equity yield estimate, since using the effective-date WAS is backward-looking (because of the roughly one-quarter lag). As the data show, the US BSL CLO equity yield has declined recently from the peak in May 2019 because of an increase in CLO debt costs (Figure 17). The European CLO equity arb has also declined, though to a lesser degree than in the US, and is still higher than 1Q19 levels (Figure 18). European CLOs have benefited from steady CLO debt costs, with new issue AAA spreads tightening materially in the past month, while loan spreads have widened marginally.


These data suggest that US CLO creation could continue in the near term, but with the arb nearing 12-month lows (ignoring late 2018/early 2019), issuance could be approaching a slowdown until CLO spreads tighten further. European CLO creation, despite the record year of issuance so far, could remain strong, as equity yields are still more attractive than in 1Q.

FIGURE 17
Estimated US BSL CLO Equity Yields Have Declined Recently



Source: Intex, S&P LCD, Barclays Research

FIGURE 18
Similar to European CLO Equity Yields



Source: Intex, S&P LCD, Barclays Research

#### **Analyst Certification**

We, Geoffrey Horton, CFA, Bradley Rogoff, CFA and Scott Schachter, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### Important Disclosures:

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

#### Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other type

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to <a href="https://publicresearch.barcap.com/S/RD.htm">https://publicresearch.barcap.com/S/RD.htm</a>. In order to access Barclays Research Conflict Management Policy Statement, please refer to: <a href="https://publicresearch.barcap.com/S/CM.htm">https://publicresearch.barcap.com/S/CM.htm</a>.

Includes content supplied by IHS Global Inc. and its affiliates ("IHS") [2019]. The use of this content was authorized in advance by IHS. Any further use or redistribution of this content is strictly prohibited without written permission by IHS. All rights reserved.

All pricing information is indicative only. Prices are sourced from Refinitiv as of the last available closing price at the time of production of the research report, unless another time and source is indicated.

## Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

## Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to <a href="https://live.barcap.com/go/research/Recommendations">https://live.barcap.com/go/research/Recommendations</a>.

#### Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

 ${\it Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)}$ 

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

#### Disclaimer

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates

(collectively and each individually, "Barclays"). It has been prepared for institutional investors only and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area ("EEA"): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143. Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an

associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2019). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

BRCF2242